Statin use in Brazil: findings and implications

References

• World Health Organization (WHO). Global Status Report on Noncommunicable Diseases 2014. WHO, 31 March 2015. Available at: https://books.google.com/books/about/Global_Status_Report_on_Noncommunicable.html?hl=&id=INoOrgEACAAJ [Last accessed 28 September 2017]
   Google Scholar
• World Health Organization (WHO). Global action plan for the prevention and control of noncommunicable diseases 2013–2020. 2013. Available at: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf [Last accessed 29 September 2017]
   Google Scholar
• Beaglehole R, Epping-Jordan J, Patel V, et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 2008;372:940-9
   PubMed Web of Science ®Google Scholar
• Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015;372:1333-41
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization (PAHO). Plan of action for the prevention and control of noncommunicable diseases. PAHO, 2014. Available: file:///C:/Users/fdb17123/Downloads/action-plan-prevention-control-ncds-americas.pdf [Last accessed 29 September 2017]
   Google Scholar
• Nashilongo MM, Singu B, Kalemeera F, et al. Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications. Cardiovasc Drugs Ther 2017;31(5-6):565-578
   Web of Science ®Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL; Lancet Commission on Essential Medicines Policies. Essential medicines for universal health coverage – authors’ reply. Lancet 2017;389:1881-2
   PubMed Web of Science ®Google Scholar
• Simoens S, Sinnaeve PR. Patient co-payment and adherence to statins: a review and case studies. Cardiovasc Drugs Ther 2014;28:99-109
   PubMed Web of Science ®Google Scholar
• Sinnott SJ, Buckley C, O’Riordan D, et al. The effect of copayments for prescriptions on adherence to medicines in publicly insured populations: a systematic review and meta-analysis. Value Health 2013;16:A207
   Web of Science ®Google Scholar
• Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97
   PubMed Web of Science ®Google Scholar
• Caires de Souza AL, de Souza ALC, de Assis Acurcio F, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy 2014;12:19-32
   PubMedGoogle Scholar
• Mansur A de P, de Padua Mansur A, Favarato D. Mortality due to cardiovascular diseases in women and men in the five Brazilian regions, 1980–2012. Arq Bras Cardiol 2016:107(2):137-146
   Web of Science ®Google Scholar
• Malta DC, Bernal RTI, de Souza M de FM, et al. Social inequalities in the prevalence of self-reported chronic non-communicable diseases in Brazil: national health survey 2013. Int J Equity Health 2016;15(1):153
   Web of Science ®Google Scholar
• Baena CP, Chowdhury R, Schio NA, et al. Ischaemic heart disease deaths in Brazil: current trends, regional disparities and future projections. Heart 2013;99:1359-64
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Choudhry NK. Improving the pathway from cardiovascular medication prescribing to longer-term adherence: new results about old issues. Circ Cardiovasc Qual Outcomes 2010;3:223-5
   PubMed Web of Science ®Google Scholar
• Rabar S, Harker M, O’Flynn N, Wierzbicki AS; on behalf of the Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405
   PubMed Web of Science ®Google Scholar
• Faludi AA, Izar M, Saraiva J, et al. Atualização da diretriz Brasileira de dislipidemias e prevenção da aterosclerose – 2017. Arq Bras Cardiol 2017;109(2 Supl 1):1-76
   Google Scholar
• Brasil. Ministério da Saúde. Portaria SMS no 200, de 25 de fevereiro 2013. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Dislipidemia para a prevenção de eventos cardiovasculares e pancreatite. Brasil: Ministerio da Saude, 25 February 2013. Available at: http://bvsms.saude.gov.br/bvs/saudelegis/sas/2013/prt0200_25_02_2013.html [Last accessed 28 August 2017]
   Google Scholar
• Nédó E, Paulik E. Association of smoking, physical activity, and dietary habits with socioeconomic variables: a cross-sectional study in adults on both sides of the Hungarian–Romanian border. BMC Public Health 2012;12:60
   PubMed Web of Science ®Google Scholar
• Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. Annu Rev Sociol 2010;36:349
   PubMed Web of Science ®Google Scholar
• Weng T-C, Yang Y-HK, Lin S-J, Tai S-H. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-51
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Lavie CJ, Serebruany VL, O’Keefe JH. Statin wars: the heavyweight match – atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med 2013;125:7-16
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22
   PubMed Web of Science ®Google Scholar
• Godman B, Burkhardt T, Bucsics A, et al. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009;9:475-84
   PubMedGoogle Scholar
• Sakshaug S, Furu K, Karlstad Ø, et al. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12:125-30
   PubMed Web of Science ®Google Scholar
• Yamauti SM, Barberato-Filho S, Lopes LC. Elenco de medicamentos do Programa Farmácia Popular do Brasil e a Política de Nacional Assistência Farmacêutica. Cadernos de Saúde Pública 2015;31:1648-62
   PubMed Web of Science ®Google Scholar
• Ribeiro RA, Duncan BB, Ziegelmann PK, et al. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian Public Health System. Arq Bras Cardiol 2014:104(1):32-43
   Web of Science ®Google Scholar
• Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87
   PubMed Web of Science ®Google Scholar
• Colantonio LD, Huang L, Monda KL, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol 2017;2:890-5
   PubMed Web of Science ®Google Scholar
• Herttua K, Martikainen P, Batty GD, Kivimäki M. Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke. J Am Coll Cardiol 2016;67:1507-15
   PubMed Web of Science ®Google Scholar
• Gomez J. InterMountain Healthcare. Heart Attack and Stroke Patients Prescribed Statin Medication Upon Discharge Have Better Long-Term Outcomes. 2017. Available at: https://intermountainhealthcare.org/news/2017/10/heart-attack-stroke-patients-prescribed-statin-medication-have-better-outcomes/ [Last accessed 30 October 2017]
   Google Scholar
• Bitton A, Choudhry NK, Matlin OS, et al. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013;126:357 e7-27
   PubMed Web of Science ®Google Scholar
• Malta DC, Szwarcwald CL. Population-based surveys and monitoring of noncommunicable diseases. Revista de Saúde Pública vol.51 supl.1 São Paulo 2017 Epub June 01, 2017, doi:10.1590/s1518-8787.201705100supl1ap
   Web of Science ®Google Scholar
• Álvares J, Goi MC, Loureiro MM, et al. National Survey on Access, Use and Promotion of Rational Use of Medicines: methods. Rev Saude Publica 2017;51:4s
   Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Azevedo e Silva G, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet 2011;377:1949-61
   PubMed Web of Science ®Google Scholar
• ABEP – Brazilian Market Research Association. Brazilian Criteria 2015 and social class distribution update for 2016. ABEP – Associação Brasileira de Empresas de Pesquisa, 2016. Available at: file:///C:/Users/fdb17123/Downloads/01_cceb_2016_11-04-16_Eng-US%20(2).pdf [Last accessed 28 August 2017]
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index 2016. WHO, 2016. Available at: http://www.whocc.no/atc_ddd_index/ [Last accessed 5 October 2017]
   Google Scholar
• Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014;10:Cd008165
   PubMed Web of Science ®Google Scholar
• Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Med 2015;13:74
   PubMed Web of Science ®Google Scholar
• Marković-Peković V, Škrbić R, Petrović A, et al. Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Rev Pharmacoecon Outcomes Res 2016;16:609-18
   PubMed Web of Science ®Google Scholar
• Nascimento RCRM, Álvares J, Guerra AA, et al. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. Rev Saúde Pública 2017;51:19s
   PubMed Web of Science ®Google Scholar
• Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. Int J Clin Pharm 2014;36:55-69
   PubMed Web of Science ®Google Scholar
• Garfield S, Clifford S, Eliasson L, et al. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011;11:149
   PubMed Web of Science ®Google Scholar
• Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2010;3:CD004371
   PubMed Web of Science ®Google Scholar
• Montgomery DC. Introduction to Linear Regression Analysis, Fifth Edition Set. Wiley, New York, USA, 2013
   Google Scholar
• O’Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clin Epidemiol 2016;8:123-32
   PubMed Web of Science ®Google Scholar
• Adedinsewo D, Taka N, Agasthi P, et al. Prevalence and factors associated with statin use among a nationally representative sample of US adults: National Health and Nutrition Examination Survey, 2011–2012. Clin Cardiol 2016;39:491-6
   PubMed Web of Science ®Google Scholar
• Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43
   PubMed Web of Science ®Google Scholar
• Farzadfar F, Finucane MM, Danaei G, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011;377:578-86
   PubMed Web of Science ®Google Scholar
• Tolonen H, Keil U, Ferrario M, Evans A; WHO MONICA Project. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol 2005;34:181-92
   PubMed Web of Science ®Google Scholar
• Bittencourt MS, Staniak HL, Pereira AC, et al. Implications of the new US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Clin Cardiol 2016;39:215-22
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816
   PubMed Web of Science ®Google Scholar
• Pavanello C, Mombelli G. Considering gender in prescribing statins: what do physicians need to know? Clin Lipidol 2015;10:499-512
   Web of Science ®Google Scholar
• Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013;56:686-95
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Kulenovic I, Falk E. Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. Cardiovasc Diabetol 2016;15:81
   PubMed Web of Science ®Google Scholar
• Guimarães RM, Andrade SSC de A, Machado EL, et al. [Regional differences in cardiovascular mortality transition in Brazil, 1980 to 2012]. Rev Panam Salud Publica 2015;37:83-9
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J, Climent E, Chillarón JJ, et al. Statins for primary cardiovascular prevention in the elderly. J Geriatr Cardiol 2015;12:431-8
   PubMedGoogle Scholar
• Gurwitz JH, Go AS, Fortmann SP. Statins for primary prevention in older adults. JAMA 2016;316:1971
   PubMed Web of Science ®Google Scholar
• Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf 2016;39:109-16
   PubMed Web of Science ®Google Scholar
• Secoli S, Danzi N, Lima F, et al. Drug interactions in patients with coronary artery disease. Rev Bras Cardiol 2011;25:11-18
   Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expet Rev Pharmacoeconom Outcomes Res 2016;16:149-52
   PubMed Web of Science ®Google Scholar
• Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expet Rev Pharmacoeconom Outcomes Res 2011;11:121-9
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
   PubMed Web of Science ®Google Scholar
• Deshpande S, Quek RGW, Forbes CA, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin 2017;33:769-78
   PubMed Web of Science ®Google Scholar
• Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol 2013;7:472-83
   PubMed Web of Science ®Google Scholar
• Silvennoinen R, Turunen JH, Kovanen PT, et al. Attitudes and actions: a survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J Clin Lipidol 2017;11:485-94
   PubMed Web of Science ®Google Scholar
• Barreto MNS de C, de Carvalho Barreto MNS, Cesse EÂP, et al. Analysis of access to hypertensive and diabetic drugs in the Family Health Strategy, State of Pernambuco, Brazil. Rev Bras Epidemiol 2015;18:413-24
   PubMedGoogle Scholar
• Helfer AP, Camargo AL, Tavares NUL, et al. Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público. Rev Panam Salud Publica 2012;31:225-32
   PubMed Web of Science ®Google Scholar
• Viacava F, Bellido JG. Condições de saúde, acesso a serviços e fontes de pagamento, segundo inquéritos domiciliares. Cien Saude Colet 2016;21:351-70
   PubMed Web of Science ®Google Scholar
• Mendes LV, Campos MR, Chaves GC, et al. Disponibilidade de medicamentos nas unidades básicas de saúde e fatores relacionados: uma abordagem transversal. Saúde em Debate 2014;38:109-123
   Google Scholar
• Nascimento RCRM, Álvares J, Guerra AA, et al. Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev Saúde Pública 2017;51:10s
   PubMed Web of Science ®Google Scholar